Combination Therapies Are Becoming the Cancer Treatment of Choice: companiesandmarkets.com

• Key factor for growth of the cancer therapy market is the expansion of target indications
• Two therapeutic classes dominate the cancer treatment sector: antineoplastics and cytostatic hormonal treatment
• Cancer risk factors: Chemical carcinogens; age; tobacco smoke; lifestyle factors; radiation; immune system; genetics

LONDON--(EON: Enhanced Online News)--A number of very specific cancer treatments – particularly those which went on to become blockbuster drugs – have gone on to receive approval for treatment of other cancer types, according to a recently released report available on companiesandmarkets.com.

The Cancer Market Outlook to 2016

http://www.companiesandmarkets.com/Market-Report/the-cancer-market-outlook-to-2016-619579.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The following types of cancer are examined in detail in the cancer market research report, with discussion of their diagnosis, treatment, management and current/forecast epidemiology: Lung; Colorectal; Breast; Ovarian; Uterine and Cervical; Leukemia; Prostate; Pancreatic; Lymphomas; Head and Neck.

The cancer treatment market is highly competitive; therefore in order to become commercial viable, pipeline therapies will have to offer a considerable improvement on the efficacy and tolerability of existing treatments, and/or be easily integrated into existing treatment regimes in combination with other drugs. Pricing is understood to be a key risk factor for those in the cancer treatment market, as the competitive nature of the industry can prove prohibitive for new targets which require high levels of investment.

Key players in the cancer market include Roche, Eli Lilly, AstraZeneca, Sanofi and Takeda. Each company is examined within the report, with particular attention focused on their strategic and growth analysis; sales focus by drug class; regional sales distribution; leading products and pipeline analysis.

Some of the current cancer treatments discussed in detail include Avastin (bevacizumab); Herceptin (trastuzumab); MabThera (rituximab); Taxotere (docetaxel) and Alimta (pemetrexed).

The June 2011, 164 page report on the cancer market provides forecast information relating to current and pipeline cancer therapies between 2010-2016. It provides a comprehensive market and industry overview including discussion of products (pipeline and current), market developments, trends, regulations, drivers/barriers to growth, and other market influencing factors.

The cancer market report assesses the pipeline details of eighteen recently launched products and enables players to ass the cost-effectiveness of the different treatments which is becoming an increasingly important aspect in recent years as budgets are squeezed.

Report Details:

http://www.companiesandmarkets.com/Market-Report/the-cancer-market-outlook-to-2016-619579.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2